Press release


30/09/2015
The Basque biotechnology company OWL will support the israeli Galmed in developing drugs against liver disease
The alliance allows the use of the non-invasive diagnostic test OWLiver in clinical trials of a drug against Non-Alcoholic Steatohepatitis (NASH) developed by Galmed.
Both companies agreed also the searching for new markers to predict a patient's response to treatment.
 
 
Documentación:
 
 
 
Permalink  
 
Developed by Web4Bio